Bisulfite-converted duplexes for the strand-specific detection and quantification of rare mutations

Significance The detection of rare mutations in clinical samples is essential to the screening, diagnosis, and treatment of cancer. Although next-generation sequencing has greatly enhanced the sensitivity of detecting mutations, the relatively high error rate of these platforms limits their overall clinical utility. The elimination of sequencing artifacts could facilitate the detection of early-stage cancers and provide improved treatment recommendations tailored to the genetic profile of a tumor. Here, we report the development of BiSeqS, a bisulfite conversion-based sequencing approach that allows for the strand-specific detection and quantification of rare mutations. We demonstrate that BiSeqS eliminates nearly all sequencing artifacts in three common types of mutations and thereby considerably increases the signal-to-noise ratio for diagnostic analyses. The identification of mutations that are present at low frequencies in clinical samples is an essential component of precision medicine. The development of molecular barcoding for next-generation sequencing has greatly enhanced the sensitivity of detecting such mutations by massively parallel sequencing. However, further improvements in specificity would be useful for a variety of applications. We herein describe a technology (BiSeqS) that can increase the specificity of sequencing by at least two orders of magnitude over and above that achieved with molecular barcoding and can be applied to any massively parallel sequencing instrument. BiSeqS employs bisulfite treatment to distinguish the two strands of molecularly barcoded DNA; its specificity arises from the requirement for the same mutation to be identified in both strands. Because no library preparation is required, the technology permits very efficient use of the template DNA as well as sequence reads, which are nearly all confined to the amplicons of interest. Such efficiency is critical for clinical samples, such as plasma, in which only tiny amounts of DNA are often available. We show here that BiSeqS can be applied to evaluate transversions, as well as small insertions or deletions, and can reliably detect one mutation among >10,000 wild-type molecules.

[1]  Bauke Ylstra,et al.  Sequencing Structural Variants in Cancer for Precision Therapeutics. , 2016, Trends in genetics : TIG.

[2]  Arthur P. Grollman,et al.  Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing , 2016, Proceedings of the National Academy of Sciences.

[3]  Sarah H. Johnson,et al.  Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers , 2016, Scientific Reports.

[4]  K. Kinzler,et al.  Diagnostic potential of tumor DNA from ovarian cyst fluid , 2016, eLife.

[5]  R. Strausberg,et al.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.

[6]  Scott R. Kennedy,et al.  Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues , 2016, Proceedings of the National Academy of Sciences.

[7]  C. Caldas,et al.  Cell‐free circulating tumour DNA as a liquid biopsy in breast cancer , 2016, Molecular oncology.

[8]  Jin-Young Jang,et al.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts. , 2015, Gastroenterology.

[9]  J. Ptak,et al.  Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord , 2015, Proceedings of the National Academy of Sciences.

[10]  K. Kinzler,et al.  Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas , 2015, Science Translational Medicine.

[11]  Ash A. Alizadeh,et al.  Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq , 2015, Expert review of molecular diagnostics.

[12]  Michael Wigler,et al.  Facilitated sequence counting and assembly by template mutagenesis , 2014, Proceedings of the National Academy of Sciences.

[13]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[14]  K. Kinzler,et al.  TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. , 2013, Cancer research.

[15]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[16]  Jason Li,et al.  Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. , 2013, Clinical chemistry.

[17]  Krishnendu Chatterjee,et al.  Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.

[18]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[19]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[20]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[21]  K. Kinzler,et al.  Evaluation of DNA from the Papanicolaou Test to Detect Ovarian and Endometrial Cancers , 2013, Science Translational Medicine.

[22]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[23]  Nicholas A. Bokulich,et al.  Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing , 2012, Nature Methods.

[24]  Jesse J. Salk,et al.  Detection of ultra-rare mutations by next-generation sequencing , 2012, Proceedings of the National Academy of Sciences.

[25]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[26]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[27]  J. Issa.  DNA methylation as a clinical marker in oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Alexander Dobrovic,et al.  Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase , 2012, Oncotarget.

[29]  K. Patterson,et al.  DNA Methylation: Bisulphite Modification and Analysis , 2011, Journal of visualized experiments : JoVE.

[30]  K. Kinzler,et al.  Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[31]  Yair Lotan,et al.  Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine Sediments , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[32]  James A. Casbon,et al.  A method for counting PCR template molecules with application to next-generation sequencing , 2011, Nucleic acids research.

[33]  S. Goodman,et al.  Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.

[34]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[35]  K. Kinzler,et al.  The Antisense Transcriptomes of Human Cells , 2008, Science.

[36]  Hanlee P. Ji,et al.  Next-generation DNA sequencing , 2008, Nature Biotechnology.

[37]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[38]  J. Slotta-Huspenina,et al.  Real-time Quantitative RT-PCR Shows Variable, Assay-dependent Sensitivity to Formalin Fixation: Implications for Direct Comparison of Transcript Levels in Paraffin-embedded Tissues , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[39]  司履生.  Cancer epigenetics , 2006 .

[40]  James R. Knight,et al.  Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.

[41]  D. Dressman,et al.  Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  K. Hillan,et al.  Unlocking the archive – gene expression in paraffin‐embedded tissue , 2001, The Journal of pathology.

[43]  G. Church,et al.  In situ localized amplification and contact replication of many individual DNA molecules. , 1999, Nucleic acids research.

[44]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Hruban,et al.  Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. , 1994, The New England journal of medicine.

[46]  S H Neoh,et al.  Quantitation of targets for PCR by use of limiting dilution. , 1992, BioTechniques.

[47]  K. Kinzler,et al.  Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. , 1992, Science.

[48]  L. E. McDonald,et al.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[50]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[51]  Y. Wataya,et al.  Reaction of sodium bisulfite with uracil, cytosine, and their derivatives. , 1970, Biochemistry.

[52]  P. Laird.  Cancer epigenetics , 2005 .

[53]  H. Hayatsu,et al.  High-speed conversion of cytosine to uracil in bisulfite genomic sequencing analysis of DNA methylation. , 2004, DNA research : an international journal for rapid publication of reports on genes and genomes.